Raise closed, search for fresh raises on Seedstage

Orange, CA

Developing AI-driven solutions to extend human health span and address aging-related diseases.

• Mission: Revolutionizing longevity treatments by integrating AI, machine learning, and biomedical research to develop therapeutics that target the genetic pathways of aging and extend human health span.  
• Innovation: Leveraging data from long-lived animal models like Methuselah Flies and crowdsourced human datasets to create AI-driven solutions that turn aging into a treatable condition.  
• Market Opportunity: Leading the fast-growing longevity market with a business model that includes direct-to-consumer products, licensing, and partnerships with pharmaceutical companies and healthcare providers.  
• Healthcare Impact: Developing treatments that not only extend life but also enhance its quality by addressing aging-related diseases and improving health span for an aging population.  
• Research Foundation: Utilizing advanced AI and cross-organism data to expedite drug discovery and develop healthspan-enhancing therapeutics, including treatments for cognitive function preservation in Alzheimer’s patients.  
• Strategic Positioning: Positioned at the forefront of longevity research, Rejuve.Bio is committed to advancing human health and well-being through innovative AI tools and collaborative partnerships.  

Rejuve.Bio is pioneering a revolutionary approach to longevity treatments by integrating advanced AI and machine learning with cutting-edge biomedical research. The company is focused on developing solutions that target the genetic pathways of aging, using data from long-lived animal models like Methuselah Flies and crowdsourced human data sets. By leveraging these insights, Rejuve.Bio aims to create therapeutics that extend human health span, turning aging into a treatable condition.

The company collaborates with a wide range of stakeholders, including pharmaceutical companies, research institutions, and healthcare providers. Their AI toolkit allows for the discovery of innovative longevity treatments, advancing the field of aging research. Additionally, their business model includes direct-to-consumer products, licensing, and partnerships, making Rejuve.Bio a leader in the fast-growing longevity market. Their goal is to improve health and well-being for an aging population by developing treatments that not only extend life but enhance its quality.

Company Info

Rejuve Biotech develops longevity therapeutics using AI and data from long-lived animal models.

Rejuve Biotech is focused on advancing human longevity through the application of artificial intelligence and data from long-lived animal models, specifically the Methuselah Fly. The company employs a unique approach that combines crowdsourced human data with advanced neural-symbolic AI to develop healthspan-enhancing products and therapeutics aimed at mitigating aging-related diseases. By leveraging a wealth of cross-organism data, Rejuve Biotech aims to shorten the drug discovery pipeline and expedite the development of effective treatments. Their research integrates genomic data from Methuselah Flies, which have been selectively bred for longevity, with human health information to identify genetic pathways relevant to aging. The company’s innovative platform has already yielded promising results, including treatments that help preserve cognitive function in Alzheimer’s patients. Rejuve Biotech operates within a tokenomically-incentivized network, collaborating with a community of scientists to explore and validate potential longevity therapies. With a focus on utilizing advanced AI tools and a rich data resource, the company is positioned to contribute significantly to the field of longevity research and therapeutics.